EryDex Low dose DSP + EryDex High dose DSP + Pooled Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nervous System Disease
Conditions
Nervous System Disease, Genetic Syndrome
Trial Timeline
Mar 2, 2017 → May 13, 2021
NCT ID
NCT02770807About EryDex Low dose DSP + EryDex High dose DSP + Pooled Placebo
EryDex Low dose DSP + EryDex High dose DSP + Pooled Placebo is a phase 3 stage product being developed by Quince Therapeutics for Nervous System Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02770807. Target conditions include Nervous System Disease, Genetic Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02770807 | Phase 3 | Completed |
Competing Products
20 competing products in Nervous System Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| filgrastim + exatecan mesylate | Daiichi Sankyo | Phase 1 | 33 |
| Methotrexate + Ibrutinib + Temozolomide | Sun Pharmaceutical | Phase 2 | 52 |
| alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcohol | Eisai | Phase 1 | 33 |
| perampanel | Eisai | Phase 2 | 52 |
| Tirabrutinib + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Tirabrutinib | Ono Pharmaceutical | Phase 1 | 33 |
| ONO-4059 + Rituximab + Methotrexate + Procarbazine + Vincristine | Ono Pharmaceutical | Phase 1 | 33 |
| Tirabrutinib + Rituximab + Temozolomide | Ono Pharmaceutical | Phase 3 | 77 |
| Tirabrutinib + Tirabrutinib + Tirabrutinib | Ono Pharmaceutical | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 1 | 33 |
| HRS-9231 + Gadobutrol | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Acalabrutinib | AstraZeneca | Phase 2 | 52 |
| Durvalumab + Acalabrutinib | AstraZeneca | Phase 1 | 33 |
| Avelumab + Lenvatinib | Merck | Phase 1 | 33 |
| temozolomide | Merck | Phase 3 | 77 |
| Ibrutinib + Pembrolizumab + Rituximab | Merck | Phase 1/2 | 41 |
| Temozolomide | Merck | Phase 2 | 52 |
| AEE788 + everolimus | Novartis | Phase 1/2 | 41 |
| vatalanib | Novartis | Phase 2 | 52 |
| EPO906 (epothilone B) | Novartis | Phase 1 | 33 |